Home Cart Sign in  
Chemical Structure| 72835-26-8 Chemical Structure| 72835-26-8

Structure of MIRA-1
CAS No.: 72835-26-8

Chemical Structure| 72835-26-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

MIRA-1 is a maleimide analogue that restores p53-dependent transcriptional activation function, inducing apoptosis in p53-mutated cells with significant antitumor activity, particularly suitable for research on p53-mutant tumors.

Synonyms: NSC 19630

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of MIRA-1

CAS No. :72835-26-8
Formula : C8H9NO4
M.W : 183.16
SMILES Code : CCC(OCN1C(C=CC1=O)=O)=O
Synonyms :
NSC 19630
MDL No. :MFCD12828765
InChI Key :YXEWPGYLMHXLPS-UHFFFAOYSA-N
Pubchem ID :227681

Safety of MIRA-1

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Normal PBMCs 0.2, 2, 20 μM 72 hours Normal PBMCs were less sensitive to NSC 19630, with an IC50 of 9.28 ± 0.23 μM. J Hematol Oncol. 2016 Nov 9;9(1):121
C91PL cells 0.2, 2, 20 μM 72 hours NSC 19630 induced apoptosis in a dose-dependent manner, with an IC50 of 2.76 ± 0.29 μM. J Hematol Oncol. 2016 Nov 9;9(1):121
ATL-derived cell lines (ED) 3 μM 48 hours NSC 19630 treatment showed significant accumulation of cells in the S-phase when compared with DMSO-exposed cells, suggesting that exposure to the helicase inhibitor induced accumulation of cells in the S-phase in ATL-derived cell lines. J Hematol Oncol. 2016 Nov 9;9(1):121
HTLV-1-transformed cell lines (MT-4, C8166, C91PL, 1186.94) 3 μM 48 hours NSC 19630 treatment showed significant accumulation of cells in the S-phase when compared with DMSO-exposed cells, suggesting that exposure to the helicase inhibitor induced accumulation of cells in the S-phase in HTLV-1-transformed and ATL-derived cell lines. J Hematol Oncol. 2016 Nov 9;9(1):121

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.46mL

1.09mL

0.55mL

27.30mL

5.46mL

2.73mL

54.60mL

10.92mL

5.46mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories